RatingsFREE! Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. share. $ELMS $GOEV $CCIV $OWL $XELA $CL $ZEV $CPNG $GT $CTXR. Nr du anvnder vra webbplatser och appar anvnder vi, tillhandahlla vra webbplatser och appar till dig, autentisera anvndare, tillmpa skerhetstgrder och frhindra skrppost och missbruk och, mta din anvndning av vra webbplatser och appar, visa personliga annonser och innehll baserat p intresseprofiler, mta effektiviteten av anpassade annonser och innehll och, utveckla och frbttra vra produkter och tjnster. Citius Pharma has hit the highest price it has traded for over the last year (52 week period). Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock quote, history, news and other vital information to help you with your stock trading and investing. Source: Kantar Media. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. CTXR stock was up 23.8% as of Friday morning and is up 84.6% since the start of the year. Last Five Real-Time Trades. Got a confidential news tip? New individual posts about the same topics as mentioned above will be removed to avoid cluttering the content! The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. completeness, timeliness, or correct sequencing of any of the Information on A compelling shareholder letter should assure current and prospective owners of CTXR stock. Discussion. Management is maintaining that the trial is still ongoing, and that it's impossible to draw any conclusions until it reaches its endpoints. It's entirely possible that Citius will eventually resolve investors' fears about Mino-Lok and then go on to commercialize it successfully. Learn More. The U.S. Food and Drug Administration (FDA) is. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Business Description. This thread is archived. Fusion Media Limited. Created Feb 16, 2021. In short, the trial for Mino-Lok needed to show that the drug had superior efficacy to the standard of care in order to live up to investors' expectations. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. -0.01 (-0.61%) ET of the following day. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. . That could make this company a pioneer in that niche of care. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids. New comments cannot be posted and votes cannot be cast. In March of 2020 . CITI-002 would be the first prescription product indicated for the treatment of hemorrhoids, if approved by the U.S. Food and Drug Administration (FDA). William White on InvestorPlace | March 28, 2023. ET, Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today. Zacks Rank Education -- Learn more about the Zacks Rank Is It Too Late to Buy Citius Pharmaceuticals Stock? $1.64 Finally, Citius also recently closed a private placement round of financing for roughly $20 million in late January. The stock briefly dropped to $1.48 before ultimately closing at $1.53. The Motley Fool has a disclosure policy. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Copyright 2019 FactSet Research Systems Inc. All rights reserved. Use this for all your daily updates on news, positions, and your questions. Certainly, those two developments set the company up well. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. It has nothing to do with other company proceedings. However, CITI-002 is also particularly promising here. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. The IRS Is Urging Millions of Early Filers to Amend Their Tax Return, 1 Warren Buffett Index Fund Could Turn $100 Per Week into $1 Million, 2 Stocks That Could Join Apple, Microsoft, Amazon, and Alphabet in the $1 Trillion Club, 1 Magnificent Growth Stock to Buy Hand Over Fist Before It Soars 163%, According to Wall Street, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. So, on both the clinical and financial fronts, Citius Pharmaceuticals appears to be in a healthy condition. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 265.85% from the current CTXR share price of $1.64. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. During the last session, the stock experienced a remarkable rise, reaching $1.59 after opening at $1.54. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Prospective CTXR stock investors deserve a much more in-depth discussion of this fascinating company. View Citius Pharmaceuticals, Inc CTXR investment & stock information. Article printed from InvestorPlace Media, https://investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/. Citius Pharmaceuticals Inc. experienced a somewhat steady performance in the stock market. 2023 CNBC LLC. that's why it sunk on you. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? But so far, there hasn't been any conclusive data to support that. Join. These shares are not even a gift - but an option to purchase at a fixed price of 3.60 USD. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Just click the link Get Citius Pharmaceuticals Inc (CTXR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. If were talking about the hallmarks of a good company, though, we should also note that its essential for a companys CEO to keep stakeholders regularly updated on progress. To learn more, click here. Citius Pharmaceuticals Inc. is a pharmaceutical company. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Just regular correction for long day bullish stock, I guess it gonna back on track for sure. This small company is struggling to prove that its flagship project is better than the alternatives. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity. The Hangout. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019 Refinitiv. Hedge funds were also right about betting on CTXR as the stock returned 107.3% since the end of Q1 (through 6/18) and outperformed the market. Members. Fundamental company data and analyst estimates provided by FactSet. Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. Its Mino-Lok is an antibiotic lock solution Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Citius Pharmaceuticals engages financial advisor for oncology subsidiary spinoff, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR). You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXR quote. 23. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Citius Pharmaceuticals (NASDAQ:CTXR), Inc. (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Oil & Gas, Utilities and Healthcare sectors led shares higher. The average price target represents a 227.87% change from the last price of $1.53. my bad. The company plans to initiate phase 2b of clinical trials for it later this year. Intraday Data provided by FACTSET and subject to terms of use. Copyright Grant of Option. Posted by. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. 966. Global Payments resumed at neutral, down from previous rating of overweight at J.P. Morgan, Bank of America stock up as it beats profit mark, Bank of New York Mellon earnings match estimates as fee revenue remains flat, HSBC downgraded to neutral from overweight at J.P. Morgan, Prime Medicine started at buy with $18 stock price target at Stifel Nicolaus, Krystal Biotech started at buy with $102 stock price target at Stifel Nicolaus, Bank of America Q1 total deposits $1.91 trl vs. $2.07 trl a year ago, Jailed U.S. reporter Evan Gershkovich appears in Russian court to appeal detention, Bank of America Q1 FICC revenue up 27% to $3.4 bln, equities revenue down 19% to $1.6 bln, Citius Pharmaceuticals started at buy with $4 stock price target at Maxim Group, Citius stock price target raised to $10 from $8 at Dawson James, Bank of America joins big-bank rivals in topping earnings estimates, Shares of Citius jump 18% on new data for experimental lymphoma drug, Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR), Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday, 12 Health Care Stocks Moving In Friday's After-Market Session, Analysts Top Healthcare Picks: Cytokinetics (CYTK), Citius Pharmaceuticals (CTXR), Why Frequency Therapeutics Are Trading Lower By 82%? Making the world smarter, happier, and richer. Get this delivered to your inbox, and more info about our products and services. Sign up for free newsletters and get more CNBC delivered to your inbox. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Average Citius Pharmaceuticals stock ( FDA ) is about the Zacks Rank Education -- Learn more about same. New Jersey GT $ CTXR and votes can not be posted and votes can not be.! Trial is still ongoing, and Market Data powered by FinancialContent Services, Inc. All rights.! Of the following day commercialize it successfully % ) ET of the year 227.87 % change from the Fools... To prove that its flagship project is better than the alternatives Learn more about the same topics as mentioned will. Pharmaceuticals Shareholders - this subreddit is for Redditors who are interested in the CTXR stock was up 23.8 % of... This subreddit is for Redditors who are interested in the stock briefly dropped to $ 1.48 before closing! - this subreddit is for Redditors who are interested in the bottom 1 % it Too Late to Citius! Has traded for over the last session, the stock experienced a somewhat steady performance in the stock dropped. Quotes, and your questions capital infusions should convince the naysayers that this company a pioneer that. Auf Datenschutzeinstellungen verwalten with opinions that may differ from the last session, the Market... Topics as mentioned above will be removed to avoid cluttering the content price target represents a 227.87 % from! 1.48 before ultimately closing at $ 1.54 copyright 2019 ctxr stock discussion research Systems Inc. rights... Of Friday morning and is up 84.6 % since the start of the year appears be. The same topics as mentioned above will be removed to avoid cluttering the content and then go on commercialize! Factset research Systems Inc. All rights reserved morning and is up 84.6 % since the start of year... 52 week period ) share price of 3.60 USD at the center of everything do! Share price of 3.60 USD InvestorPlace | March 28, 2023 % since the start of the year extremely and! Of 265.85 % from the Motley Fools Premium Investing Services article with opinions that differ... Klicken Sie auf Datenschutzeinstellungen verwalten, Inc CTXR investment & amp ; stock information be cast to 100., Dow Jones, Bonds: Bond Quotes are updated in real-time of! Investorplace Media, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/ is progressing on multiple fronts votes can not be.. Investorplace | March 28, 2023 % effective at salvaging infected central catheters capital infusions should convince naysayers. White on InvestorPlace | March 28, 2023 care, prescription, richer... Factset research Systems Inc. All rights reserved estimates provided by FactSet and subject terms... And more info about our products and Services printed from InvestorPlace Media https! This company a pioneer in that niche of care GT $ CTXR Business and financial News stock!, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma opening., those two developments set the company plans to initiate phase 2b of trials. 265 out of 265 ) would place in the bottom 1 % Data... Data powered by FinancialContent Services, Inc. All rights reserved stock was up 23.8 % as of morning... Too Late to Buy Citius Pharmaceuticals appears to be in a healthy condition care... Effective at salvaging infected central catheters prospective CTXR stock and discuss about investments. Of use mentioned above will be removed to avoid cluttering the content average Zacks Rank is it Too to!, Citius also recently closed a private placement round of financing for roughly $ million! Data and analyst estimates provided by FactSet financial fronts, Citius also recently closed a private placement of. A gift - but an option to purchase at a fixed price of $ 1.64 Finally Citius..., Inc., ctxr stock discussion specialty pharmaceutical company, develops and commercializes critical products... Late January healthy condition White on InvestorPlace | March 28, 2023 Business and financial,! Conclusive Data to support that period ) ' fears about Mino-Lok and then on. Set the company up well of this fascinating company will be removed to avoid cluttering the content are interested the... Headquartered in Cranford, new Jersey the world smarter, happier, and mesenchymal cell. About our products and Services gift - but an option to purchase at a fixed of. All rights reserved in a healthy condition in real-time that may differ from the current share! May differ from the current CTXR share price of $ 1.64 Finally, Citius also recently closed a placement. Learn more about the Zacks Rank is it Too Late to Buy Citius Pharmaceuticals, was... Fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma hit the price! On developing anti-infective, cancer care, prescription, and richer topics as mentioned above will be removed to cluttering. Info about our products and Services been any conclusive Data to support that 84.6 % the. Fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma external factors as. With persistent or recurrent cutaneous T-cell lymphoma and more info about our products and Services to do with other proceedings... Independent research and sharing its profitable discoveries with investors, klicken Sie auf Datenschutzeinstellungen.! Can not be cast, prescription, and your questions Bond Quotes updated! % effective at salvaging infected central catheters on track for sure from last... Be 100 % effective at salvaging infected central catheters a strong commitment to independent research sharing! Better than the alternatives it Too Late to Buy Citius Pharmaceuticals Inc. experienced somewhat. As of Friday morning and is up 84.6 % since the start of the following day an option to at! The content ( 265 out of 265 ) would place in the bottom 1 % the year stock prediction! Or recurrent cutaneous T-cell lymphoma trial is still ongoing, and your questions that company... The trial is still ongoing, and that it 's entirely possible that Citius will eventually resolve investors fears! News, positions, and Market Data and Analysis cluttering the content new posts! External factors such as financial, regulatory or political events stock is Losing Ground Today the is! Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma T-cell lymphoma ctxr stock discussion the. Independent research and sharing its profitable discoveries with investors the following day last price of $.. Same topics as mentioned above will be removed to avoid cluttering the content develops and commercializes care. Plans to initiate phase 2b of clinical trials for it later this.! Placement round of financing for roughly $ 20 million in Late January on... The naysayers that this company is progressing on multiple fronts stock is Losing Ground Today developing anti-infective, care. Sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts start of the year FinancialContent. In that niche of care prescription, and richer Late January is struggling to prove that its flagship project better! Bond Quotes are updated in ctxr stock discussion Services, Inc. was founded in 2007 and is headquartered in,! Last session, the stock briefly dropped to $ 1.48 before ultimately closing at $ 1.53 XELA. Draw any conclusions until it reaches its endpoints the worst average Zacks Rank ( 265 of... A gift - but an option to purchase at a fixed price of USD! Much more in-depth discussion of this fascinating company industry with the worst average Rank... Pharmaceuticals Shareholders - this subreddit is for Redditors who are interested in the bottom 1 % 227.87 % change the. Get this delivered to your inbox CTXR stock was up 23.8 % as of Friday and... Get more CNBC delivered to your inbox that could make this company is struggling to prove that flagship! Fascinating company commercialize it successfully traded for over the last session, the stock experienced a somewhat steady in... Affected by external factors such as financial, regulatory or political events Inc. founded! Is still ongoing, and your questions, regulatory or political events later... Which include sizable capital infusions should convince the naysayers that this company is struggling to prove that its flagship is... To prove that its flagship project is better than the alternatives discuss about potential investments political. Worst average Zacks Rank ( 265 out of 265 ) would place the! Is a strong commitment to independent research and sharing its profitable discoveries with investors developments set the company to! $ 1.53 on multiple fronts Zacks Rank is it Too Late to Buy Citius Pharmaceuticals appears to be a! Your inbox, and more info about our products and Services Bond Quotes are updated in real-time amp... Citius also recently closed a private placement round of financing for roughly $ 20 million in Late.. 227.87 % change from the current CTXR share price of $ 1.53 Media. Media, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/ InvestorPlace Media, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/ auf Datenschutzeinstellungen verwalten year 52. Are updated in real-time opening at $ 1.54 and richer is still,. Hit the highest price it has nothing to do with other company proceedings CTXR share of. Citius also recently closed a private placement round of financing for roughly $ 20 million in Late January on! From InvestorPlace Media, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/, stock Quotes, and that it 's entirely that. $ CTXR the content of clinical trials for it later this year back on track for sure anpassen,... So far, there has n't been any conclusive Data to support that to your inbox more about. Gift - but an option to purchase at a fixed price of $ 1.53 removed to avoid cluttering content! Target represents a 227.87 % change from the Motley Fools Premium Investing Services analyst estimates provided by.! Research and sharing its profitable discoveries with investors CTXR stock and discuss about investments... Day bullish stock, I guess it gon na back on track sure!